OSLO, Norway, Aug 16, 2017 /PRNewswire/ -- Nordic Nanovector ASA (OSE: NANO), a biopharmaceutical company focusing on the development and commercialisation of novel targeted therapeutics for haematological cancers, will announce its second quarter 2017 results on Wednesday, 23rd of August 2017.
A presentation by Nordic Nanovector’s senior management team will take place at 8:30 am CEST at:
Thon Hotel Vika Atrium, Munkedamsveien 45, 0250 Oslo
Meeting Room: BJØRVIKA
The presentation will be recorded as a webcast and will be available at www.nordicnanovector.com in the section: Investor Relations/Webcast.
The results report and the presentation will be available at www.nordicnanovector.com in the section: Investor Relations/Reports and Presentation/Quarterly Reports/2017 from 7:00 am CEST the same day.
For further information, please contact:
IR enquiries:
Tone Kvåle, Chief Financial Officer
Cell: +47-91-51-95-76
Email: ir@nordicnanovector.com
MediaEnquiries
Mark Swallow/David Dible/Marine Perrier (Citigate Dewe Rogerson)
Tel: +44-207-638-9571
Email: nordicnanovector@citigatedr.co.uk
About Nordic Nanovector:
Nordic Nanovector is committed to develop and deliver innovative therapies to patients to address major unmet medical needs and advance cancer care. The company aspires to become a leader in the development of targeted therapies for haematological cancers.
Nordic Nanovector’s lead clinical-stage candidate is Betalutin®, a novel CD37-targeting Antibody-Radionuclide-Conjugates (ARC) designed to advance the treatment of non-Hodgkin’s Lymphoma (NHL). NHL is an indication with substantial unmet medical need, representing a growing market forecast to be worth nearly USD 20 billion by 2024.
The Company aims to rapidly develop Betalutin®, alone and in combination with other therapies, for the treatment of major types of NHL, targeting first regulatory submission in relapsed/refractory follicular lymphoma in 1H 2019. Nordic Nanovector intends to retain marketing rights and to actively participate in the commercialisation of Betalutin® in core markets.
The Company is also advancing a pipeline of ARCs and other immunotherapies for multiple cancer indications.
Further information about the Company can be found at www.nordicnanovector.com
This information was brought to you by Cision http://news.cision.com
View original content:http://www.prnewswire.com/news-releases/nordic-nanovector-asa-invitation-to-second-quarter-2017-results-presentation-and-webcast-300505184.html
SOURCE Nordic Nanovector
